Last reviewed · How we verify
NCT03621462
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
NA trial testing Artificial Intelligence Dermatology Assistant (AIDA™) in Melanoma (Skin) in 4,000 participants. Status unknown.
1 September 2020
Quick facts
| Lead sponsor | Elucid Labs Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 4,000 |
| Start date | 15 October 2018 |
| Primary completion | 1 September 2020 |
| Estimated completion | 15 October 2020 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Artificial Intelligence Dermatology Assistant (AIDA™)
Conditions studied
- Melanoma (Skin) — all drugs for Melanoma (Skin) →
- Basal Cell Carcinoma of the Skin — all drugs for Basal Cell Carcinoma of the Skin →
- Squamous Cell Carcinoma of the Skin — all drugs for Squamous Cell Carcinoma of the Skin →
Sponsor
Elucid Labs Inc.
Who can join
18 and older, any sex, with Melanoma (Skin) or Basal Cell Carcinoma of the Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diagnosis of melanoma involves physical examination of the lesion with many dermatologists adjunctively employing dermoscopes. The rate of misdiagnosis of melanoma remains significant, along with a high rate of referral to biopsy. Elucid Labs (Waterloo, Ontario) has developed a novel handheld, digital dermoscope with accompanying visualization and analysis software - the Artificial Intelligence Dermatology Assistant (AIDA™). Apart from collecting conventional demoscopic images, AIDA also collects images at various spectral bands. The aim of this study is to understand and quantify the value of this novel adjunctive information for dermatologists diagnosing atypical skin lesions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03621462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma (Skin)
Currently open trials in the same condition.
- NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
- NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
- NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
- NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
- NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03621462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elucid Labs Inc.
- Last refreshed: 8 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03621462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing